Edition:
United States

Profile: CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

119.47AUD
26 Jul 2016
Change (% chg)

$-1.39 (-1.15%)
Prev Close
$120.86
Open
$119.34
Day's High
$119.96
Day's Low
$118.71
Volume
1,112,761
Avg. Vol
1,027,220
52-wk High
$121.25
52-wk Low
$87.11

CSL Limited is a biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent serious and rare medical conditions. The principal activities of the Company include research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The Company operates through the three segments: CSL Behring, which manufactures and develops plasma therapies (plasma products and recombinants), bioCSL, which manufactures and distributes non-plasma biotherapeutic products, and CSL Intellectual Property, which includes licensing of intellectual property generated by the Company to unrelated third parties. CSL Behring therapies are indicated for treatment of bleeding disorders including, hemophilia and von Willebrand disease, primary and secondary immune deficiencies, hereditary angioedema, neurological disorders and inherited respiratory disease. bioCSL manufactures seasonal and pandemic influenza vaccines.

Company Address

CSL Ltd

45 Poplar Rd
MELBOURNE   VIC   3052
P: +613.93891911
F: +613.93891434

Company Web Links